Viatris Gets FDA Nod for Generic Sandostatin, Shares Regulatory Updates [Yahoo! Finance]
Viatris Inc. (VTRS)
Company Research
Source: Yahoo! Finance
These achievements outline the company's R&D progress in 2025. VTRS will continuously work with health bodies across the world to advance its pipeline further. The FDA approved Viatris' octreotide acetate for injectable suspension, a generic equivalent of Sandostatin LAR Depot. The product is indicated for patients who have responded to and tolerated subcutaneous Sandostatin Injection for the treatment of acromegaly, severe diarrhea and flushing associated with metastatic carcinoid tumors, and profuse watery diarrhea related to vasoactive intestinal peptide-secreting tumors. This marks VTRS' first approved injectable using microsphere technology. The FDA approval is also VTRS' fourth injectable approval in 2025, following iron sucrose, paclitaxel and liposomal amphotericin B. The approval strengthens VTRS' generics portfolio with technically complex, high-value products. The FDA has accepted for review VTRS' new drug application (NDA) for an investigational low-dose estrogen
Show less
Read more
Impact Snapshot
Event Time:
VTRS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VTRS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VTRS alerts
High impacting Viatris Inc. news events
Weekly update
A roundup of the hottest topics
VTRS
News
- Viatris to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026, and Host Investor Event on March 19, 2026PR Newswire
- Mapi Pharma to Present New Safety and Efficacy Data from Glatiramer Acetate Depot Long-Acting Injection Phase II Study in Patients with Primary Progressive Multiple Sclerosis (PPMS) at ACTRIMS Forum 2026 [Yahoo! Finance]Yahoo! Finance
- Viatris Appoints Matthew J. Maletta as Chief Legal Officer [Yahoo! Finance]Yahoo! Finance
- Viatris Appoints Matthew J. Maletta as Chief Legal OfficerPR Newswire
- What Are Wall Street Analysts' Target Price for Viatris Stock? [Yahoo! Finance]Yahoo! Finance
VTRS
Earnings
- 11/6/25 - Beat
VTRS
Sec Filings
- 2/4/26 - Form SCHEDULE
- 2/3/26 - Form 8-K
- 1/2/26 - Form 4
- VTRS's page on the SEC website